Alessia Lucia Daverio

Dr. Alessia Lucia Daverio

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ADAlessia Lucia Daverio
Alessia Lucia Daverio
ACAlessandro Coccarelli
Alessandro Coccarelli
THThéophraste Henry
Théophraste Henry
ADAlina Danu
Alina Danu
LALaurentiu Agrigoroaie
Laurentiu Agrigoroaie
Desiree DeandreisDesiree Deandreis
Desiree Deandreis
Background/Objectives: Multiple myeloma (MM) is a complex hematologic malignancy characterized by abnormal plasma cell proliferation in the bone marrow. [18F]FDG PET/CT has emerged as a key imaging modality, demonstrating high sensitivity and specificity for the detection of metabolically active disease compared with conventional imaging techniques. This review examines the role of PET/CT imaging in evaluating therapeutic response in symptomatic myeloma, including minimal residual disease (MRD) assessment. Methods: We surveyed the literature published between 2014 and 2024 across PubMed, Scopus, Web of Science, and the Cochrane Library for peer-reviewed articles evaluating PET imaging in the assessment of treatment response in multiple myeloma. Results: [18F]FDG PET/CT provides a whole-body assessment of disease burden, extramedullary involvement detection, and early metabolic response evaluation. Standardized response assessment criteria (Deauville, IMPeTUs, IMWG) have enhanced the reproducibility and accuracy of treatment monitoring. Semiquantitative parameters including SUVmax and metabolic tumor volume (MTV) provide useful prognostic information with PET negativity correlating with improved progression-free and overall survival. The integration of PET/CT with bone marrow assessment techniques (next-generation flow cytometry and sequencing) optimizes MRD evaluation and patient stratification. Conclusions: PET/CT represents a valuable imaging tool for improving therapeutic decision making and risk stratification in MM management. Emerging radiotracers beyond FDG, including [11C]choline, [11C]methionine, and targeted agents like [68Ga]pentixafor and CD38-targeted immunoPET tracers, hold promise for enhanced diagnostic capabilities in specific clinical contexts.